# GSK Announces Recipients of Linked by Lupus: Optimal Care Initiative Grants Nearing $1 Million
**Date:** 2026-01-20 09:00:00
**Company:** GSK plc
**Ticker:** GSK
**Source URL:** https://www.businesswire.com/news/home/20260115842061/en/GSK-Announces-Recipients-of-Linked-by-Lupus-Optimal-Care-Initiative-Grants-Nearing-1-Million/
---
Jan 20, 2026 9:00 AM Eastern Standard Time
# **GSK Announces Recipients of Linked by Lupus: Optimal Care Initiative Grants Nearing $1 Million**
Share
* * *
- Grant funding awarded to support lupus-focused community programs across the United States
PHILADELPHIA--( [BUSINESS WIRE](https://www.businesswire.com/))--GSK plc (LSE/NYSE: GSK) has announced the recipients of the Linked by Lupus: Optimal Care Initiative grant, awarding nearly $1 million to support national, state, and local non-profit organizations working to improve the lives of people impacted by lupus, including systemic lupus erythematosus (SLE) and lupus nephritis (LN).
GSK previously...
# GSK Announces Recipients of Linked by Lupus: Optimal Care Initiative Grants Nearing $1 Million
**Date:** 2026-01-20 09:00:00
**Company:** GSK plc
**Ticker:** GSK
**Source URL:** https://www.businesswire.com/news/home/20260115842061/en/GSK-Announces-Recipients-of-Linked-by-Lupus-Optimal-Care-Initiative-Grants-Nearing-1-Million/
---
Jan 20, 2026 9:00 AM Eastern Standard Time
# **GSK Announces Recipients of Linked by Lupus: Optimal Care Initiative Grants Nearing $1 Million**
Share
* * *
- Grant funding awarded to support lupus-focused community programs across the United States
PHILADELPHIA--( [BUSINESS WIRE](https://www.businesswire.com/))--GSK plc (LSE/NYSE: GSK) has announced the recipients of the Linked by Lupus: Optimal Care Initiative grant, awarding nearly $1 million to support national, state, and local non-profit organizations working to improve the lives of people impacted by lupus, including systemic lupus erythematosus (SLE) and lupus nephritis (LN).
GSK previously sought proposals for community-driven initiatives aimed at improving earlier diagnosis and recognition of lupus signs and symptoms; enhancing awareness of and access to evidence-based treatment options; and/or advancing communication between patients and providers regarding lupus.
“We’re proud to support these organizations that are deeply embedded in their communities and uniquely positioned to drive meaningful change,” **Court Horncastle, Senior Vice President at GSK, said**. “Their work is essential to improving the lupus journey, from diagnosis to treatment to ongoing care, and we’re honored to help bring their visions to life.”
Launched in [June 2025](https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fus.gsk.com%2Fen-us%2Fmedia%2Fpress-releases%2Fgsk-announces-the-linked-by-lupus-optimal-care-initiative-to-help-support-individuals-with-lupus-in-the-us%2F&esheet=54398107&newsitemid=20260115842061&lan=en-US&anchor=June+2025&index=1&md5=80c5300356d4c9fb86b5cd54e8829e3f), the Linked by Lupus: Optimal Care Initiative is part of GSK’s ongoing commitment to improving outcomes for people living with lupus. These efforts align with the initiative’s mission to foster a more connected, informed, and supported lupus community. The selected organizations include 13 grantees from across the country, chosen for their innovative, community-led programs designed to improve earlier diagnosis, enhance awareness of and access to evidence-based treatment, and advance communication between patients and providers.
The 2025 Linked by Lupus grant recipients include:
- Autoimmune Association, Clinton Township, MI
- American Kidney Fund, Rockville, MD
- AME Zion Health Ministry, Rochester, NY
- Kaleidoscope Fighting Lupus, Marylhurst, OR ( _funded for 2026_)
- LatinaStrong Foundation, Peoria, Arizona
- Looms For Lupus, Baldwin Park, CA
- Lupus Foundation of America Texas Gulf Coast Chapter, Houston, TX
- Lupus Foundation of America, Greater Ohio Chapter, Brecksville, OH
- Lupus Foundation of America, Wisconsin Chapter, Milwaukee, WI
- Lupus LA, Los Angeles, CA
- Michigan Lupus Foundation, Traverse City, MI
- National Kidney Foundation, New York, NY
- We Are ILL, USA
**Anne Marie Blacketer, CFRE, CEO of Lupus Texas Gulf Coast**, an independent, locally based chapter of the Lupus Foundation of America, takes her lead from the community. Blacketer said, “We listened closely as members shared their need for greater education and awareness about lupus, including how to access the high-quality healthcare they deserve. From diagnostic testing and physicians who truly understand the disease to learning about and obtaining impactful treatments—these are the resources and support we work to provide to individuals and their health partners.”
As this work moves forward, GSK remains committed to supporting initiatives that strengthen and uplift lupus communities nationwide. These investments represent only one step in a long-term effort to advance meaningful change, expand access to resources, and empower those affected by lupus.
More information about future funding opportunities is available [here](https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.gsk.com%2Fen-gb%2Fresponsibility%2Fgrants-and-donations%2F&esheet=54398107&newsitemid=20260115842061&lan=en-US&anchor=here&index=2&md5=d8420e72744f4e9e77b35d39c4fa9113).
**About GSK** GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at [gsk.com](https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.gsk.com&esheet=54398107&newsitemid=20260115842061&lan=en-US&anchor=gsk.com&index=3&md5=ac2ef995491980205ba4934fcbe21c6c).
**Cautionary statement regarding forward-looking statements** GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described in the “Risk Factors” section in GSK’s Annual Report on Form 20-F for 2024, and GSK’s Q3 Results for 2025.
**Registered in England & Wales:** No. 3888792
**Registered Office:** 79 New Oxford Street
London
WC1A 1DG
## Contacts
**GSK inquiries** Media
Kathleen Quinn, +1 202 603 5003 (Washington DC)
Lyndsay Meyer, +1 202 302 4595 (Washington DC)
Investor Relations:
Jeff McLaughlin, +1 215 751 7002 (Philadelphia)
Frannie DeFranco, +1 215 751 3126 (Philadelphia)
Industry:
- [Biotechnology](https://www.businesswire.com/newsroom?industry=1000039)
- [Pharmaceutical](https://www.businesswire.com/newsroom?industry=1000146)
- [Health](https://www.businesswire.com/newsroom?industry=1000088)
[](https://www.gsk.com/en-gb/responsibility/grants-and-donations/)
### GSK plc
NYSE:GSK
* * *
Release Versions
[English](https://www.businesswire.com/news/home/20260115842061/en/GSK-Announces-Recipients-of-Linked-by-Lupus-Optimal-Care-Initiative-Grants-Nearing-%241-Million)
* * *
### Contacts
**GSK inquiries** Media
Kathleen Quinn, +1 202 603 5003 (Washington DC)
Lyndsay Meyer, +1 202 302 4595 (Washington DC)
Investor Relations:
Jeff McLaughlin, +1 215 751 7002 (Philadelphia)
Frannie DeFranco, +1 215 751 3126 (Philadelphia)
More News From GSK plc
Get RSS Feed
[**Exdensur (depemokimab) approved by US FDA for the treatment of severe asthma**](https://www.businesswire.com/news/home/20251216764904/en/Exdensur-depemokimab-approved-by-US-FDA-for-the-treatment-of-severe-asthma)
PHILADELPHIA--( [BUSINESS WIRE](https://www.businesswire.com/))--GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved Exdensur (depemokimab-ulaa) as an add-on maintenance treatment of severe asthma characterised by an eosinophilic phenotype in adult and pediatric patients aged 12 years and older. The FDA approval of Exdensur is based on data from the SWIFT-1 and SWIFT-2 phase III trials. In these studies, depemokimab demonstrated sustained exacerbation reduction with two doses per...
[**GSK Announces US FDA Approval of Benlysta (Belimumab) for Pediatric Patients With Active Lupus Nephritis**](https://www.businesswire.com/news/home/20220727005841/en/GSK-Announces-US-FDA-Approval-of-Benlysta-Belimumab-for-Pediatric-Patients-With-Active-Lupus-Nephritis)
LONDON--( [BUSINESS WIRE](https://www.businesswire.com/))--GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved Benlysta (belimumab) for the treatment of children aged 5 to 17 with active lupus nephritis (LN) who are receiving standard therapy. Lupus nephritis is a serious inflammation of the kidneys caused by lupus, which can lead to end-stage kidney disease, requiring dialysis or a kidney transplant.i The approval extends the current indication in the US to include both lupus and...
[**GSK announces FDA approval for Nucala (mepolizumab) for use in adults with chronic rhinosinusitis with nasal polyps**](https://www.businesswire.com/news/home/20210729006206/en/GSK-announces-FDA-approval-for-Nucala-mepolizumab-for-use-in-adults-with-chronic-rhinosinusitis-with-nasal-polyps)
LONDON--( [BUSINESS WIRE](https://www.businesswire.com/))--GSK announces FDA approval for Nucala (mepolizumab) for use in adults with chronic rhinosinusitis with nasal polyps....
[Back to Newsroom](https://www.businesswire.com/newsroom)
[](https://www.gsk.com/en-gb/responsibility/grants-and-donations/)
### GSK plc
NYSE:GSK
* * *
Release Versions
[English](https://www.businesswire.com/news/home/20260115842061/en/GSK-Announces-Recipients-of-Linked-by-Lupus-Optimal-Care-Initiative-Grants-Nearing-%241-Million)
* * *
### Contacts
**GSK inquiries** Media
Kathleen Quinn, +1 202 603 5003 (Washington DC)
Lyndsay Meyer, +1 202 302 4595 (Washington DC)
Investor Relations:
Jeff McLaughlin, +1 215 751 7002 (Philadelphia)
Frannie DeFranco, +1 215 751 3126 (Philadelphia)
## Wish your news had this kind of reach?
[Sign Up](https://www.businesswire.com/sign-up/account) [Learn About Business Wire](https://www.businesswire.com/why-business-wire)